PLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protalix Biotherapeutics Inc (PLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant trading trends, and no recent positive news or catalysts make this stock less appealing for immediate investment. While technical indicators show some bullish trends, the overall sentiment and financials suggest holding off for now.
The MACD histogram is slightly positive at 0.00749, indicating a weak bullish trend. RSI is neutral at 26.221, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support levels are at 2.153 and 2.088, while resistance levels are at 2.363 and 2.428. However, the stock's price is currently below the pivot point of 2.258, suggesting limited upward momentum.
Bullish moving averages and low put-call ratios in the options market suggest some positive sentiment.
Significant YoY declines in revenue (-49.93%), net income (-184.76%), and EPS (-216.67%) in the latest quarter (2025/Q4). No recent news or significant trading trends from hedge funds or insiders. Lack of congress trading data or influential figure activity.
In 2025/Q4, the company's revenue dropped to $9,122,000 (-49.93% YoY), net income fell to -$5,504,000 (-184.76% YoY), EPS declined to -0.07 (-216.67% YoY), and gross margin decreased to 49.36 (-37.26% YoY). This indicates poor financial health and declining performance.
No recent analyst ratings or price target changes available for analysis.
